image credit- shutterstock
In a pivotal stride toward advancing cancer care, Mumbai-based startup Qure.ai, a leader in artificial intelligence (AI) solutions for medical imaging, and Project Data Sphere, a nonprofit initiative of the US-based CEO Roundtable on Cancer, have announced their partnership to augment tumour assessments using artificial intelligence (AI)-enabled solutions for clinical trials and cancer care.
The collaboration aims to increase efficiency and consistency in evaluating the effectiveness of cancer treatments, ultimately improving the quality of care for patients.
The focus of this collaboration is autoRECIST, a product of Project Data Sphere’s Images and Algorithms programme. The programme, initiated in consultation with the US Food and Drug Administration (FDA), includes stakeholders and experts from across the pharmaceutical industry and academia.
In collaboration with Qure.ai, autoRECIST will address the critical need for automating and standardising tumour response assessments in medical imaging to enhance cancer treatment and research. Rooted in current imaging guidelines, this AI clinical tool will aid radiologists in the detection, selection, measuring and tracking of lesions using defined criteria.
